Tigderimus

Drug Profile

Tigderimus

Alternative Names: IMM 125; Oxeclosporin; SDZ IMM 125

Latest Information Update: 09 Aug 2002

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Class Antiasthmatics; Antineoplastics
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Asthma; Cancer
  • Discontinued Psoriasis; Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 19 Sep 1997 Oxeclosporin is now called tigderimus
  • 19 Sep 1997 A preclinical study has been added to the Obstructive Airways Disease pharmacodynamics section
  • 11 Nov 1996 A preclinical study has been added to the Obstructive Airways Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top